Related Experiment Video

Updated: Dec 21, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance

Andrea Bild1, Jia-Ling Teo2, Michael Kahn2

  • 1Department of Medical Oncology & Therapeutics Research, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

Cancer Drug Resistance (Alhambra, Calif.)
|May 20, 2020
PubMed

Insights

Targeting cancer stem cells (CSCs) could reverse therapy resistance. This perspective discusses targeting Kat3 coactivator/Catenin pathways to eliminate CSCs without harming normal stem cells.

Area of Science:

  • Cancer Biology
  • Stem Cell Biology
  • Molecular Oncology

Background:

  • Cancer cells exhibit significant heterogeneity.
  • Cancer stem cells (CSCs) or tumor-initiating cells (TICs) drive tumor formation, therapeutic resistance, and relapse.
  • Eliminating CSCs is a key strategy to overcome treatment resistance.

Purpose of the Study:

  • To explore strategies for eliminating CSCs to reverse therapeutic resistance.
  • To discuss the potential of targeting "cancer stemness" pathways.
  • To address the challenge of eliminating CSCs without impacting normal stem cell populations.

Main Methods:

  • Reviewing the role of CSCs in tumorigenesis and therapy resistance.
  • Discussing pharmacological targeting of CSC surface markers or "stemness" pathways.
  • Examining differential Kat3 coactivator/Catenin usage as a transcriptional control mechanism.

Main Results:

  • CSCs are central to cancer initiation, resistance, and relapse.
  • Targeting CSCs offers a potential route to reverse therapy resistance.
  • Differential Kat3 coactivator/Catenin usage is a fundamental mechanism in stem cell biology.

Conclusions:

  • Eliminating CSCs is critical for overcoming cancer therapeutic resistance.
  • Pharmacological targeting of Kat3 coactivator/Catenin pathways presents a promising strategy.
  • This approach aims to eliminate CSCs while preserving normal stem cell function and integrity.
Keywords:
CREB-binding proteinKat3 coactivatorcancer stem cellp300stem celltherapy resistance

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
2.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K